Enterprise Value

79.91M

Cash

16.66M

Avg Qtr Burn

N/A

Short % of Float

0.39%

Insider Ownership

5.42%

Institutional Own.

28.49%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZONISADE (Zonisamide) (ET-104) Details
Rare genetic disease, Neurological disorder

Approved

Update

Carbaglu® (carglumic acid tablets) Details
Hyperammonemia NAGS deficient, chronic hyperammonemia

Approved

Quarterly sales

Approved

Quarterly sales

Biorphen® (phenylephrine HCI) Details
Hypotension (vasodilation in the setting of anesthesia)

Approved

Quarterly sales

EPRONTIA (Topiramate Oral Solution) (ET-101) Details
Tonic-clonic seizures / seizures / migraine

Approved

Quarterly sales

Approved

Quarterly sales

Cysteine hydrochloride injection (generic - ANDA) Details
Additive to amino acid solutions to meet the nutritional requirements of newborn infants

Approved

Quarterly sales

Nitisinone Capsules Details
Tyrosinemia type 1, Rare diseases

Approved

Quarterly sales

ALKINDI® SPRINKLE (hydrocortisone) Details
Adrenocortical Insufficiency (Pediatrics)

Approved

Quarterly sales

ET-400 Details
Rare genetic disease

NDA

Acceptance for review

ET-600 Details
Rare diseases, Diabetes insipidus

NDA

Submission

NDA

FDA meeting

Lamotrigine Oral Suspension (ET-105) Details
Seizures, Epilepsy, Lennox-Gastaut syndrome

Failed

Discontinued